$36.05
Today
as of Jul 22, 16:45 ET
Last 30 days
Recent Press Releases & News
AGIO Shares Sink Nearly 7% After Scrapping the Tebapivat SCD Program
Why Agios Pharma, A Novo Rival, Just Pulled A Bearish Move
Agios scraps sickle cell drug programme on underwhelming Phase II data
Overview
52-week range
$22
$46
58% of range
Avg surprise (last 2)
+1.5%
Avg reaction (last 1)
+4.2%
100% positive
Latest IV / EM
72%
EM ±16.4% · $35 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Mar 31, 2026 | Mar 2026 | $-1.69 | — | — | — | — | financials |
| Tue Sep 30, 2025 | Sep 2025 | $-1.78 | — | — | — | — | financials |
| Thu Jul 31, 2025 | Jun/2025 | $-1.93 | $-1.74 | -10.9% | — | — | earnings |
| Thu May 1, 2025 | Mar/2025 | $-1.55 | $-1.80 | +13.9% | — | +4.2% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $16.22 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-1.69 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-1.45 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-1.64 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-1.51 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Jul 30, 2026 | Jun/2026 | BMO | -$1.86 | -$1.93 | +3.6% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | $1M | — | $2M | $2M | $1M | — | $783,000 | $1M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-110M | — | $-117M | $-127M | $-107M | — | $-103M | $-106M |
| Net income | $-99M | — | $-103M | $-112M | $-89M | — | $948M | $-96M |
| EPS (diluted) | $-1.69 | — | $-1.78 | $-1.93 | $-1.55 | — | $16.22 | $-1.69 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $114M | $89M | $93M | $81M | $79M | $76M | $254M | $85M |
| Inventory | $35M | $33M | $32M | $31M | $30M | $28M | $26M | $24M |
| Total current assets | $835M | $942M | $1.03B | $1.02B | $969M | $966M | $1.07B | $632M |
| Total assets | $1.18B | $1.30B | $1.39B | $1.47B | $1.56B | $1.66B | $1.79B | $773M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $76M | $104M | $101M | $102M | $89M | $122M | $165M | $113M |
| Total equity | $1.11B | $1.19B | $1.28B | $1.37B | $1.47B | $1.54B | $1.63B | $661M |